Indian firms Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma won the bids conducted by the Chinese health mi...

"The company already has a strong code of conduct and an anti-bribery and anti-corruption clause in its contracts with all its vendors. The...

Shanghvi’s salary for 2013-14 was Rs 2.73 crore, according to data sifted by ET from filings of leading listed drug companies.

The combined market share of Sun Pharma (5.4% at present) and Ranbaxy (3.8%) will be 9.2%; much higher than that of the current No. 1 playe...

The government had cleared a Rs 5,168 crore proposal of US-based pharma firm Mylan Inc's to acquire Indian generic drugs company Agila Spec...

The pharma sector, estimated to be around Rs 1.5 lakh cr, recorded single digit growth for the first time in many years on account of deepe...

Faced with rush of multinationals to acquire Indian pharma firms, the Commerce and Industry Ministry is proposing to tighten the FDI policy...

The DIPP said current norms must lay down the foundation of what should be the nature of Indian drug companies in the long term.

The government is likely to finalise FDI policy with regard to existing drug companies ahead of the FIPB meeting on July 5.

With no let up in multinationals seeking nod to acquire stake in Indian pharma firms despite government putting norms to check it.

Despite Novartis setback on cancer drug patent plea, multinational pharma firms cannot ignore emerging markets such as India and China.

While the company's performance in the June quarter was strong sequentially, it will be interesting to see GSK's strategies to overcome the...

South Africa-based drug maker Adcock Ingram has quietly acquired privately-held Cosme Farma for Rs 480 crore, a 13 times premium over Cosme...

India's attempts to check foreign investment in pharma and expand drug pricing control could force multinationals to exit the country.

The health ministry will put on hold its plans to grant permissions to multinational pharma firms for conducting phase I clinical trials of...

The domestic pharma sector’s better-than-global-average growth is creating new streams of allied business in this Rs 27,000-crore industry.

The new excise duty regime for pharmaceuticals is expected to trigger a shift in the outsourcing business, touted as a big opportunity for ...